Product Description
The research-grade biosimilar is a fully human IgG1 monoclonal antibody that binds to the ?-subunit domain of IGF-1R. IGF-1R is overexpressed in orbital fibroblasts of patients suffering from thyroid eye disease. Thyroid eye disease is a manifestation of Graves disease that is associated with inflammation of orbital muscles and fatty tissues. Although the mechanism of action of the original drug has not yet been fully characterized, binding of the drug to IGF-1R has been reported to internalize and degrade the receptors, and thus inhibit tissue inflammation and remodeling associated with Thyroid eye disease. In 2020, the US FDA approved the application of the drug to treat Graves-associated ophthalmopathy
Biovision | A2160 | Anti-IGF-1R (Teprotumumab), Human IgG1 Antibody DataSheet
Antibody Target: IGF-1R
Target Alternative Name: RO4858696-000, R-1507, RV-001, IGFR, CD221, IGFIR, JTK13
Tag Line: The biosimilar is a human monoclonal antibody that targets human insulin-like growth factor 1 receptor (IGF-1R) signaling and inhibits downstream inflammatory pathophysiology underlying Thyroid Eye Disease (TED)
Category: Biosimilars
Host: Recombinant
Isotype: IgG1
Species Reactivities: Human
Immunogen Sequence: Human IGF-1R
Accession #: DB06343
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE